Skip to content
WhiteLab Genomics logo

WhiteLab Genomics

WhiteLab Genomics is a YC Winter 2022 (W22) company. Based in Paris, Île-de-France, France; Boston, MA, USA. Team of 40.

  • Artificial Intelligence
  • Gene Therapy
  • Cell Therapy
  • Genomics

About WhiteLab Genomics

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

WhiteLab Genomics builds an AI platform that helps biotech and pharma companies design molecular constructs for cell, RNA, and DNA therapies. It serves drug developers working on genomic medicines, predicting optimal therapeutic candidates from biological data at the earliest stages of R&D. The platform replaces largely manual, trial-and-error molecular design work, compressing the time and cost of moving from target to candidate.

Go-to-market

WhiteLab Genomics sells to pharmaceutical and biotech companies, including large enterprises such as Sanofi and Cytiva, through direct partnerships and collaborative research agreements.

From the Y Combinator listing

How WhiteLab Genomics describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Unleashing the potential of DNA and RNA based therapies using AI

We have developed an AI platform enabling to accelerate the discovery and the design of genomic therapies such as Cell Therapies, RNA Therapies and DNA Therapies.

Facts

Industry
Healthcare / Healthcare -> Drug Discovery and Delivery
Location
Paris, Île-de-France, France; Boston, MA, USA
Team size
40
Status
Active
Stage
Growth

Founders (2)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works